P&G to copromote Novartis’ Enablex
Executive Summary
Procter & Gamble Pharmaceuticals will copromote Novartis' overactive bladder treatment Enablex (darifenacin), companies announce July 6. Partnership covers promotion and further development of Enablex extended-release tablets for treatment of OAB in the U.S. Agreement provides P&G and Novartis option to "collaborate in the over-the-counter commercialization should both parties decide to pursue that opportunity"...